WW International, Inc. (WW) - 10-K Filing Summary
Business Context and Reporting Period
Reporting Period: Fiscal Year 2025 ended December 31, 2025. Due to a change in fiscal year end following bankruptcy, this period includes four extra days compared to a standard calendar year.
Key Event: The Company emerged from Chapter 11 bankruptcy on June 24, 2025 (the "Emergence Date"). Consequently, the financial statements are presented using "Fresh Start Accounting," distinguishing between the "Predecessor" period (Dec 29, 2024 – June 24, 2025) and the "Successor" period (June 25, 2025 – Dec 31, 2025).
Business Model: WW operates as a single segment with two primary business lines: Behavioral (digital subscriptions and workshops) and Clinical (Med+ offering access to clinicians and GLP-1 medications). The Company is pivoting to a fully integrated model for the GLP-1 era.
Key Financial Metrics
| Metric | Successor Period (Jun 25 - Dec 31, 2025) |
Predecessor Period (Dec 29, 2024 - Jun 24, 2025) |
Fiscal 2024 (Full Year) |
|---|---|---|---|
| Revenue, Net | $347.1 million | $363.6 million | $785.9 million |
| Gross Profit | $247.1 million | $263.4 million | $533.1 million |
| Gross Margin | 71.2% | 72.4% | 67.8% |
| Operating (Loss) Income | $(2.3) million | $21.2 million | $(236.2) million |
| Net (Loss) Income | $(62.1) million | $1,118.1 million | $(345.7) million |
| Adjusted EBITDA | $65.3 million | $87.7 million | $146.5 million |
| Cash and Cash Equivalents | $160.3 million | $53.0 million | $53.0 million |
| Total Debt (Long-Term) | $465.5 million | $1,430.6 million | $1,430.6 million |
Note: The Predecessor Net Income of $1,118.1 million includes a non-cash reorganization gain of $1,143.9 million related to debt discharge and fresh start adjustments.
Material Changes vs. Prior Period
- Revenue Decline: Combined Fiscal 2025 Subscription Revenue was $705.4 million, a 9.2% decrease from Fiscal 2024 ($777.0 million). This was driven by a 15.2% decline in Behavioral Subscription Revenue, partially offset by a 44.7% increase in Clinical Subscription Revenue.
- Subscriber Trends: End of Period Behavioral Subscribers decreased 18.9% to 2.63 million. Conversely, Clinical Subscribers increased 41.9% to 130.2 thousand.
- Debt Restructuring: Pre-bankruptcy debt of approximately $1.6 billion (Term Loans, Revolver, and Notes) was discharged. The Company emerged with a new $465.0 million Term Loan Facility maturing in 2030.
- Asset Impairments: The Predecessor period recorded $27.5 million in franchise rights impairments. No goodwill impairments were recorded in the current period.
- Cost Structure: Operating expenses decreased in the Successor period compared to the Predecessor period, reflecting cost-saving initiatives and a shift to a more variable cost structure.
Guidance, Outlook, and Risks
Management Commentary: Management views the combined Predecessor and Successor results as the most meaningful comparison for trends. The decline in Behavioral revenue is attributed to recruitment challenges and bankruptcy-related media coverage. The growth in Clinical revenue is driven by consumer demand for weight management medications (GLP-1s).
Liquidity: The Company believes its sources of liquidity (cash and operating cash flows) are sufficient to meet obligations for at least 12 months. However, the New Term Loan Facility requires mandatory prepayments of excess unrestricted cash above $100 million.
Key Risks:
- Bankruptcy Aftermath: Risks related to maintaining vendor/member relationships and executing the business plan post-emergence.
- Competition: Intense competition in the clinical weight management market and from free/low-cost "do-it-yourself" alternatives affecting the Behavioral business.
- Regulatory: Evolving regulations regarding GLP-1s, telehealth, and data privacy (GDPR, CCPA).
- Technology: Risks associated with cybersecurity and the integration of AI into offerings.
Investor Verification Checklist
- Subscriber Retention: Verify the sustainability of the 18.9% decline in Behavioral subscribers and the ability of the Clinical business to offset this loss in the long term.
- Debt Covenants: Review the specific financial covenants and mandatory prepayment triggers in the new $465 million Senior Secured Credit Agreement.
- Intangible Asset Valuation: Scrutinize the assumptions used in the Fresh Start Accounting valuation of the $529 million in new intangible assets (Trade Name, Technology, Customer Relationships).
- Cash Flow Sustainability: Assess whether operating cash flows can consistently cover the new debt service obligations without requiring further refinancing.
- Regulatory Compliance: Monitor ongoing regulatory scrutiny regarding the marketing and prescribing of GLP-1 medications and telehealth practices.